Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Phase 2, 6-month Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies

NCT05225415 is registered in ClinicalTrials.gov with Cognition Therapeutics as lead sponsor.

NCT NCT05225415
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05225415 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Phase 2, 6-month Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies
Lead sponsor
Cognition Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
May 19, 2022
Completion date
November 25, 2024
Enrollment
130 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

dementia with lewy bodies